A considerable number of infectious agents have been classified as human carcinogens Group 1 by the International Agency for Research on Cancer. Major infection-related cancers such as cancers of nasopharynx (53%), stomach (60%) and liver (63%) occur in the World Health Organization Western Pacific Region. Many infection-related cancers are preventable, particularly those associated with human papilloma virus, Helicobacter pylori, human immunodeficiency virus-I, hepatitis B virus and hepatitis C virus and liver flukes. Mongolia shows the highest prevalence of hepatitis B virus and hepatitis C virus, and China shows the highest prevalence of Helicobacter pylori. Chronic infection is attributable for 17-28% of overall cancer incidence or mortality in China, Japan and Korea. Through infant immunization for hepatitis B, 30 of 37 countries and areas in the Western Pacific Region have reached the 2012 milestone of chronic hepatitis B virus infection prevalence of <2% in 5-year-old children and countries and areas of the region are now striving toward reaching the regional goal of <1% by 2017. Human papilloma virus immunization program is implemented either by government funding or, in some low-income countries, by public and private sector organizations. Cervical cancer screening via visual inspection with acetic acid or Pap smear is available in many Western Pacific Region Member States. More efforts are needed to implement new World Health Organization guide to vaccinate 9-to 13-year-old girls with two doses of human papilloma virus vaccine, and use human papilloma virus tests to screen women to prevent and control cervical cancer including guaranteed monitoring and appropriate follow-up for abnormal results.
In 2008, ∼2 million of the 12.7 million new cancer cases were estimated to be attributable to infections. Of the 2 million new cancer cases, 68.5% (1.37 million) occured in Asia (2) .
Infection-related cancers are avoidable and preventable, particularly those associated with hepatitis B virus (HBV), hepatitis C virus (HCV) and human papillomavirus (HPV); also liver flukes (specifically in endemic areas in Southeast Asia and East Asia), human immunodeficiency virus-I (HIV-1) and Helicobacter pylori (3) (4) (5) (6) .
In this article, we aim (i) to review the burden of infection-related cancer incidence in the WHO Western Pacific Region (WPR) and (ii) to describe the prevalence of cancer-related infectious agents and population attributable fraction (PAF) of infectious agents on cancer in selected countries which have available data. In addition, we review (iii) the prevention programmes of cervical cancer including HPV vaccination, of liver cancer with hepatitis B and C control, as well as liver fluke management and of stomach cancer with H. pylori control specifically in Asian countries of WPR and current WHO recommendations.
Patients and methods
Data on estimated cancer cases for the Member States (MS) of WPR were extracted from GLOBOCAN 2012 (http://globocan.iarc.fr/ Default.aspx) and MS were grouped into (i) Asian countries; (ii) Australia and New Zealand; (iii) Pacific Islands (three subgroups based on data availability from GLOBOCAN) (7).
Data on the prevalence of five cancer-related infectious agents, HBV, HCV, H. pylori HPV and Clonorchis sinensis in seven AsianPacific countries were extracted from the scientific literature. Studies reporting prevalence of infectious agents published through 30 June 2014 were identified using PubMed (http://www.ncbi.nlm.nih.gov/pubmed/).
The search keywords were 'prevalence' and each infectious agent and name of the country. Information on PAFs of Korea, Japan and China was summarized from the published literature.
Cancer-related information from the WP Regional Action Plan for the Prevention and Control of NCD (2014-20) (8) and from NCD Country Capacity Survey 2013 which assessed national capacity for NCD prevention and control were extracted (9) . The WHO website on hepatitis B and C vaccination programme and HPV vaccination and related information was also reviewed (10). Table 2 shows the burden of infection-related cancers in the GLOBO-CAN 2012. The proportion of overall cancer cases in WPR is ∼30% among world estimated cancer cases. However, the proportion of cancer cases of nasopharynx, stomach and liver in WPR among world cases (53, 60 and 63%, respectively) are much higher than other cancers. Non-Hodgkin's lymphoma (22%) and Hodgkin's lymphoma (7%) are not so frequent in the WPR and 18% of cervical cancer was occurred in the WPR. Tables 3 and 4 show the prevalence of cancer-related infectious agents among selected Asian-Pacific countries. The global incidence of hepatocellular carcinoma (HCC) and cirrhosis are high and are predominantly due to chronic HBV and HCV infections. According to one analysis, in 2010, an estimated 341 000 persons died of HBV-related HCC and 312 000 from cirrhosis due to HBV (11) . The WPR region is responsible for ∼50% of global liver cancer, the majority due to chronic HBV and HCV infection (11) . The highest burden of liver cancer, and the highest number of HBV and HCV infections is in fact seen in China. The high numbers in China determine the burden of liver cancer globally (Box 1). The prevalence of HBV was highest in Mongolia and the lowest in Japan and Australia (12) . Due to introduction of HBV immunization program, the prevalence among children is low compared with that of adults in the WPR. Mongolia also showed the highest prevalence for HCV (8.7-15.6%) (13) . HCV transmission continues to be driven by unsafe medical injections and procedures, and sharing of contaminated injecting equipment among people who inject drugs (14-16). Helicobacter pylori prevalence was the highest in China (63%) and the lowest in Australia. Wide variance in prevalence of H. pylori according to age groups was observed, usually low prevalence among younger age groups. Prevalence of HPV was ∼35-39% in Mongolia, New Zealand and Australia, 22-24% in Korea and Japan, and ∼10% in China. Clonorchis sinensis was no longer epidemic or showed very low prevalence in most countries; however Republic of Korea and China showed 1.8-2.4% of prevalence.
Results

Burden of infection-related cancer in WPR
Prevalence of infectious agents in selected Asian-Pacific countries
The number of new HIV infections among adults in low-and middle-income countries has been decreased by 30% between 2001 and 2012, as well as in Asia and the Pacific regions (17) . The estimated number of people living with HIV in East Asia was 370 000 in the year 2001 and 880 000 in 2012 (17) . In South and Southeast Asia, the estimated numbers were 3 700 000 in 2001 and 3 900 000 in 2012, respectively (17) . Table 5 shows comparison of information on PAFs by infections agents in Korea, Japan and China. The estimated PAFs for infectionrelated cancer incidence were 24.5% for men and 15.4% for women in the Republic of Korea (23) . The corresponding PAFs were 22.8% for men and 17.5% for women in Japan (24) as well as 28.8% for men and 21.8% for women in China (21) . These estimates were much higher than those from France (3.7%) (25) and the UK (3.1%) (26) . These PAFs, however, have limitation of adopting PAFs from other regions for EBV on nasopharyngeal cancer and Hodgkin's lymphoma and for HPV on cervical cancer due to limited epidemiological evidence from these regions (27) .
PAF of infectious agents
WHO recommendations for the prevention of infection-related cancers
Transmission of hepatitis B and C, both, can be prevented through screening blood units for hepatitis B and C and applying universal standard precautions in particular safe injection practices (28-31). In 2012, 70% countries had a national blood policy, compared with 
Box 1. Liver cancer attributable to hepatitis B and C viruses in China
China alone accounts for 55% of hepatocellular carcinoma (HCC) cases worldwide. Currently, the estimated incidence of liver cancer is 33.7/100 000 for men and 10.5/ 100 000 for women, and the estimated numbers of 5-year prevalence of HCC in China is estimated to be 2 201 000 men and 708 000 women (7). HCC is now the fifth most common cancer in urban areas and the third common in rural areas, and it ranks as the second leading cause of cancer-related deaths in males and the third leading cause of cancer-related deaths in females, with a total mortality rate of 23.76 per 100 000 persons (18) . In China, hepatitis B virus (HBV) is the biggest factor for developing HCC; ∼85% of Chinese HCC cases are HBV related, 10% of cases are hepatitis C virus (HCV) related (19) (20) (21) . Based on the latest (2006) population-based serosurvey, China has 93 million HBsAg carriers (7.18% of the population), including ∼20 million people in need of HBV treatment (22) . Approximately 50% of persons who develop HCC die within a year of diagnosis. An estimated 7 million people are infected with HCV (22).
60% countries in 2004. Overall, 62% countries have specific legislation covering the safety and quality of blood transfusion have specific legislation covering the safety and quality of blood transfusion. Effective and cheap interventions to prevent transmission of sexually transmitted infections, hepatitis B and C and HIV include consistent condom use and harm reduction for people who inject drugs, most importantly the provision of clean injecting equipment (32, 33) . A very cost-effective intervention for prevention and control of infection-related cancers is hepatitis B immunization (34) . The current WHO recommendation is to vaccinate all infants against HBV with a dose within 24 h of life (or as soon as possible) followed by two additional doses in infancy (34) . In 2010, 179 countries reported that national infant immunization programmes included the Hepatitis B vaccine (35) . This is a major increase compared with 31 countries in 1992, the year the World Health Assembly passed a resolution to recommend universal vaccination against hepatitis B. Intervention to prevent mother-to-child transmission of hepatitis B from HBsAgpositive mothers to newborns (hepatitis B immune globulin and hepatitis B vaccine within 12 h of birth) will also contribute to prevent cancers caused by HBV (34) .
The WPR of WHO has led the way in hepatitis B control as the first Region to establish a time-bound goal to reduce childhood chronic infection rates (36) . Through hepatitis B immunization 30 out of 37 countries and areas have reached the 2012 milestone of reducing the rate of chronic hepatitis B infection among 5-year-old children to <2% (37) . The target is now to further reduce HBV infection rates to <1% by 2017 (38). However, adults who have not been vaccinated continued to die from hepatitis B-related liver disease and liver cancer although chronic active hepatitis B can be treated (39) . Chronic HBV infection remains hyper-endemic in China and many other countries in the Region with prevalence rates of >6% among adults who may progress to HCC (40). Both birth-dose and three-dose vaccine coverage have steadily increased in the Western Pacific, which now has the highest rates of coverage of any WHO region (41). In 2012, 20 million newborn infants (86% of newborn infants in the Region) received a hepatitis B birth dose within 24 h of birth, while 22 million infants (96%) completed the three-dose hepatitis B vaccination (Fig. 1) .
Most adults (∼75%) infected with HCV develop chronic HCV infection, which is associated with significant morbidity and mortality. There are now new medications that bear the potential to cure HCV infection in >90% of persons treated with minimal side effects with >50 drugs in the development pipeline (42) . A cure will considerably reduce the risk of developing liver cancer in those with chronic active HCV infection and plausibly might reduce the risk of transmission. However, the exorbitant cost for HCV drugs is a major barrier. WHO recommends that people who inject drugs have access to WHO recommended harm reduction interventions in particular the use of clean injecting equipment and drug treatment (32) .
Many infection-related cancers are avoidable and preventable, particularly those associated with HPV, HBV and HCV; also liver flukes (specifically in endemic areas in Southeast Asia and East Asia), and H. pylori. Among them, prevention of liver cancer through hepatitis B immunization and prevention of cervical cancer through screening, visual inspection with acetic acid (VIA) or Pap smear (cervical cytology), if cost-effective, linked with timely treatment of pre-cancerous lesions, are the very cost-effective interventions for the prevention and control of cancer (8) . Vaccination against human papillomavirus is listed as an indicator of national system response in the comprehensive global monitoring framework for the prevention and control of NCDs (8) . Prophylactic HPV vaccines have shown nearly 100% efficacy in preventing pre-cancerous lesions of the cervix due to HPV types 16 and 18, among previously uninfected individuals. Seventeen (47%) countries and areas-mostly high-income and upper middle-income-in the WPR have implemented governmentfunded national HPV vaccination programmes (Table 6) , and an additional five countries have conducted pilot HPV vaccination projects (43) . However, ∼30% of cervical cancers globally and in Asia are caused by HPV types not covered by current vaccines (44) . WHO recommends a comprehensive approach to cervical cancer control, including both HPV vaccination and screening through VIA or Pap smear cervical cytology linked with timely treatment of pre-cancerous lesions. Cervical cytology is available in Asian countries in the WPR except for Cambodia, the Philippines and Vietnam; however, only two-thirds of Pacific Island countries have capacity for cervical cytology in the primary healthcare setting. VIA is available in 11 countries in the region (Table 6 ). The use of VIA with or without cryotherapy at the same visit has to be considered. However, many low-income countries are not having adequate laboratory facilities for cytology. Regardless of the screening method used, monitoring and appropriate follow-up mechanisms for abnormal results must also be in place.
The treatment of clonorchiasis/opistochiasis (infestated by C. sinensis and Opistorchis viverrini, respectively) may prevent the development of cholangiocarcinoma, cancer of the bile duct, although the incidence of cholagiocarcinoma is relatively rare. For the purposes of public health control of clonorchiasis/opistochiasis, WHO recommends carrying out community diagnosis at the district level, and implementing preventive chemotherapy with praziquantel.
Helicobacter pylori infection can be treated, however, clear evidence on effectiveness, feasibility and safety of H. pylori eradication has not yet been provided. There is now greater understanding of the process of gastric carcinogenesis, and the role of bacterial virulence factors interacting with host immune responses. Although there is ongoing research that explores the role of vaccination against H. pylori for the prevention of gastroduodenal diseases, this still remains experimental. A recent AsiaPacific Gastric Cancer Consensus meeting has recommended a strategy of H. pylori screening and eradication in high-risk populations to reduce gastric cancer incidence (45) . Recent meta-analysis showed the efficacy of H. pylori eradication therapy on prevention of metachronous lesions or gastric cancer among patients with gastric pathology or after endoscopic resection of gastric neoplasm (46) .
HIV is an often overlooked cause of cancer in particular hematopoietic cancers (3) (4) (5) . Global efforts for HIV reduction, including reducing sexual or vertical transmission as well as transmission by unsafe drug use and improvement of accessibility for antiretroviral treatment (17) are expected to contribute to prevention of HIV-related cancer sites such as Kaposi's sarcoma and lymphomas. HIV prevention efforts in Asia have reduced new HIV infections since early 2000 albeit the decrease has been stagnating over the past 8 years (47). Cancer incidence in HIV-infected patients is currently not included in the NCD surveillance framework. A better understanding on the PAF of HIV on cancer incidence is needed.
Conclusion
WHO Regional action plan for the prevention and control of NCDs, which includes cancer, targets a reduction in premature mortality from NCDs by 25% by 2025. Global targets are also set for risk factors of cancer such as tobacco use, harmful use of alcohol, physical inactivity and salt/sodium intake. The comprehensive NCD surveillance framework includes monitoring of cancer incidence as one the 25 indicators.
The high burden of infectious agents causing cancer in Asia is an unprecedented opportunity to link the prevention and control of noncommunicable diseases to communicable diseases. Initial steps could be improved surveillance and disease burden estimates of cancer caused by infectious agents. While we have some data for liver cancer and cervical cancer, other infectious agents are less well documented in the context of NCDs.
The proportion of the most common infection-related new cancer cases in the WPR, such as cervix, liver and stomach cancers, is ∼25%, however, these cancer cases could be prevented. In addition, lifestyle modification such as stopping smoking, no harmful use of alcohol, increased physical activity as well as healthy diet, reduced salt intake will contribute to the reduction of cancer risk and burden. In addition, priority for national cancer prevention strategies is needed to be settled Table 6 . Availability of screening tests for cervical cancer at the primary healthcare level and government-funded routine HPV vaccination, Western Pacific Region (9) according to the prevalence of infectious agents as well as the burden of infection-related cancers.
